Top videos
Dr. Jawad has been performing Bariatric Surgery in Central Florida since 1984, and Laparoscopic Bariatric Surgery since 1999, having completed over 2000 Bariatric Surgical Cases safely, and with great success. Here you can watch Dr. Jawad performing a Laparoscopic Roux-En-Y Gastric Bypass surgery, with audio commentary describing the procedure.
Pleurisy is a condition in which the pleura — a membrane consisting of a layer of tissue that lines the inner side of the chest cavity and a layer of tissue that surrounds the lungs — becomes inflamed. Also called pleuritis, pleurisy causes sharp chest pain (pleuritic pain) that worsens during breathing. A variety of underlying conditions can cause pleurisy. Treatment of pleurisy involves pain control and treating the underlying condition.
Cerebral hydatid disease (neurohydatidosis) is caused by Echinococcus granulosus or less commonly E. alveolaris or E. multilocularis. The larval stage is the cause of hydatid disease in humans 1. Epidemiology Cerebral hydatid disease is a rare parasitic infestation and accounts for 1-2 % of all cystic echinococcosis. Hydatid disease is endemic in the Mediterranean region, the Middle East, Africa, eastern part of Turkey, Australia and parts of South America 2. Clinical presentation Symptoms and signs include: focal neurological deficits headaches increased intracranial pressure hydrocephalus papilloedema and loss of vision altered mental status seizures (rare)
ACL tears are treatable using arthroscopy and minimally-invasive surgical techniques. The surgical success rates for ACL reconstruction exceed 95%. The anterior cruciate ligament is one of the major supportive ligaments in the knee
TransMedics’ proprietary Organ Care System (OCS) is the first commercial and portable warm blood perfusion organ transport system. With the OCS, doctors are able to perform “living organ transplants,” where organs are kept warm and functioning in a controlled environment from the time they are recovered to the moment they are placed in the recipient’s body.
A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant. The average time from investigational new drug (IND) filing to market was 6.7 years for 11 mABs approved between 1994 and 2003 but shot up to 8.3 years for 12 mAbs approved between 2004 and March 9, 2011, according to Deloitte Recap LLC’s analysis, Therapeutic Monoclonal Antibodies – Insights, Strategies and Data.